Home Cart Sign in  
Chemical Structure| 1000676-41-4 Chemical Structure| 1000676-41-4

Structure of Lirilumab
CAS No.: 1000676-41-4

Chemical Structure| 1000676-41-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lirilumab is a humanized IgG4 monoclonal antibody that blocks the interaction of KIR receptors with their ligands. Lirilumab has potential for research in various cancers such as acute myeloid leukemia.

Synonyms: IPH2102

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lirilumab

CAS No. :1000676-41-4
M.W : 145.52 kDa
SMILES Code : NONE
Synonyms :
IPH2102

Safety of Lirilumab

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Normal cervical squamous cells 20 µg/ml 24 hours Lirilumab had no lytic effect on normal cervical squamous cells Front Oncol. 2022 Jan 31;12:747482
Natural killer cells (NK cells) 20 µg/ml 24 hours Lirilumab promoted NK cell-mediated lysis of HPV+ cervical cancer cells in a dose-dependent manner Front Oncol. 2022 Jan 31;12:747482
93VU tumor cells 10 μg/mL 24 hours To evaluate the effect of Lirilumab on NK cell-mediated killing of HNSCC cells, results showed that Lirilumab had a weaker killing effect on 93VU cells. Head Neck. 2019 Aug;41(8):2591-2601
JHU029 tumor cells 10 μg/mL 24 hours To evaluate the effect of Lirilumab on NK cell-mediated killing of HNSCC cells, results showed that Lirilumab significantly enhanced NK cell-mediated killing of JHU029 cells. Head Neck. 2019 Aug;41(8):2591-2601
 

Historical Records

Categories